

Correction

Correction for: PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer

Zhixuan Ren^{1,*}, Li Wang^{2,*}, Chaohui Leng³

¹Department of Radiation Oncology, Huadong Hospital, Fudan University, Shanghai 200433, P.R. China

²Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, P.R. China

³Department of Oncology, Jiujiang University Affiliated Hospital, Jiujiang 332000, P.R. China

*Equal contribution

Correspondence to: Chaohui Leng; email: huposetang@i.smu.edu.cn

Keywords: NSCLC, PTPRD, immune checkpoint inhibitors, nomogram, TCGA

Original article: *Aging (Albany NY)* 2023; 15: pp 8204–8219

PMID: [37602864](https://pubmed.ncbi.nlm.nih.gov/37602864/)

PMCID: [PMC10497019](https://pubmed.ncbi.nlm.nih.gov/PMC10497019/)

doi: [10.18632/aging.204964](https://doi.org/10.18632/aging.204964)

This article has been corrected: The authors found that name of the last/corresponding author has been mistakenly recorded as Chaohui Leng, and the correct name should be Zhaohui Leng. In addition, the order of the author's affiliations was also corrected.

The corrected version of the **authors list and affiliations** are provided below:

Zhixuan Ren^{1,2,*}, Li Wang^{3,*}, Zhaohui Leng¹

¹Department of Oncology, Jiujiang University Affiliated Hospital, Jiujiang 332000, P.R. China

²Department of Radiation Oncology, Huadong Hospital, Fudan University, Shanghai 200433, P.R. China

³Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, P.R. China

*Equal contribution

Correspondence to: Zhaohui Leng; email: huposetang@i.smu.edu.cn